Reported financial results for the three and twelve months finished December 31 today.

The primary determinant of the charge was an increase in share price during the fourth quarter of 2013 and its own resulting impact on the Black-Scholes valuation of the warrants.2 million non-cash charge for the extinguishment of the original Hercules loan that was paid upon the signing of the new debt arrangement. December 31 For the twelve months ended, 2013, AcelRx reported a net loss of $23.4 million, or $0.59 per share, weighed against a net loss of $33.4 million, or $1.51 per share for the same period in 2012.4 million recognized from the Grunenthal upfront payment, the $14.1 million in non-cash expense resulting from the liability accounting linked to the warrants issued in connection with the PIPE financing completed in June 2012 and the $1.2 million one-time, noncash charge connected with our debts renegotiation, adjusted net reduction for 2013 was $35.5 million, or $0.89 per share.Furthermore, Melanie Bloom, national individual spokesperson for the Coalition to Prevent Deep-Vein Thrombosis, will receive ASH’s Outstanding Assistance Award in acknowledgement of her commitment to increasing public knowing of DVT on Sunday, 6 December, from 1:30 – 2:00 p.m. This year’s Practice Forum, ‘New Health-Care Policies and the Practice of Hematology,’ will address how new health-care guidelines shall have an effect on medical practice, including a dialogue of changes in reimbursement that are anticipated by Medicare this year 2010.